* Regulus Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Regulus Therapeutics Inc is for a loss of 22 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 2.1% in the last three months.
* Wall Street's median 12-month price target for Regulus Therapeutics Inc is $6.00, above its last closing price of $2.43.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.40 -0.39 -0.40 Missed -1.3
Sep. 30 2023 -0.41 -0.40 -0.40 Met -0.8
Jun. 30 2023 -0.41 -0.41 -0.37 Beat 9.8
Mar. 31 2023 -0.44 -0.44 -0.42 Beat 3.8
Jan. -0.51 -0.40 Beat 21.6
1 0001
Sep. 30 2022 -0.49 -0.49 -0.50 Missed -2
Jun. 30 2022 -0.49 -0.48 -0.50 Missed -3.1
Mar. 31 2022 -0.56 -0.53 -0.50 Beat 6.2
This summary was machine generated May 7 at 16:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments